Global Tuberculosis (TB) Diagnostics Market Analysis and Forecast 2024-2030
Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term 'consumption' came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.
According to APO Research, The global Tuberculosis (TB) Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Global Tuberculosis (TB) Diagnostics key players include Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, etc. Global top five manufacturers hold a share about 33%.
APAC is the largest market, with a share over 40%, followed by Americas and Europe, both have a share about 40 percent.
In terms of product, Culture-based is the largest segment, with a share about 33%. And in terms of application, the largest application is Hospitals, followed by Diagnostic Laboratories.
Report Includes
This report presents an overview of global market for Tuberculosis (TB) Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Tuberculosis (TB) Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for Tuberculosis (TB) Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Tuberculosis (TB) Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Tuberculosis (TB) Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Tuberculosis (TB) Diagnostics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, Hologic, Qiagen, BioMerieux and Hain Lifescience, etc.
Tuberculosis (TB) Diagnostics segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis (TB) Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis (TB) Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis (TB) Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Tuberculosis (TB) Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Tuberculosis (TB) Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tuberculosis (TB) Diagnostics revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Chapter 13: The main concluding insights of the report.
According to APO Research, The global Tuberculosis (TB) Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Global Tuberculosis (TB) Diagnostics key players include Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, etc. Global top five manufacturers hold a share about 33%.
APAC is the largest market, with a share over 40%, followed by Americas and Europe, both have a share about 40 percent.
In terms of product, Culture-based is the largest segment, with a share about 33%. And in terms of application, the largest application is Hospitals, followed by Diagnostic Laboratories.
Report Includes
This report presents an overview of global market for Tuberculosis (TB) Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Tuberculosis (TB) Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for Tuberculosis (TB) Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Tuberculosis (TB) Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Tuberculosis (TB) Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Tuberculosis (TB) Diagnostics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, Hologic, Qiagen, BioMerieux and Hain Lifescience, etc.
Tuberculosis (TB) Diagnostics segment by Company
- Danaher
- Roche
- Thermo Fisher Scientific
- BD
- Abbott
- Hologic
- Qiagen
- BioMerieux
- Hain Lifescience
- Oxford Immunotec
- Culture-Based Diagnostics
- Sputum Smear Microscopy
- Rapid Molecular Diagnostics
- Others
- Diagnostic Laboratories
- Hospitals
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis (TB) Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis (TB) Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis (TB) Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Tuberculosis (TB) Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Tuberculosis (TB) Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tuberculosis (TB) Diagnostics revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Chapter 13: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Tuberculosis (TB) Diagnostics Market by Type
1.2.1 Global Tuberculosis (TB) Diagnostics Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Culture-Based Diagnostics
1.2.3 Sputum Smear Microscopy
1.2.4 Rapid Molecular Diagnostics
1.2.5 Others
1.3 Tuberculosis (TB) Diagnostics Market by Application
1.3.1 Global Tuberculosis (TB) Diagnostics Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Diagnostic Laboratories
1.3.3 Hospitals
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 TUBERCULOSIS (TB) DIAGNOSTICS MARKET DYNAMICS
2.1 Tuberculosis (TB) Diagnostics Industry Trends
2.2 Tuberculosis (TB) Diagnostics Industry Drivers
2.3 Tuberculosis (TB) Diagnostics Industry Opportunities and Challenges
2.4 Tuberculosis (TB) Diagnostics Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Tuberculosis (TB) Diagnostics Market Perspective (2019-2030)
3.2 Global Tuberculosis (TB) Diagnostics Growth Trends by Region
3.2.1 Global Tuberculosis (TB) Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Tuberculosis (TB) Diagnostics Market Size by Region (2019-2024)
3.2.3 Global Tuberculosis (TB) Diagnostics Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Tuberculosis (TB) Diagnostics Revenue by Players
4.1.1 Global Tuberculosis (TB) Diagnostics Revenue by Players (2019-2024)
4.1.2 Global Tuberculosis (TB) Diagnostics Revenue Market Share by Players (2019-2024)
4.1.3 Global Tuberculosis (TB) Diagnostics Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Tuberculosis (TB) Diagnostics Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Tuberculosis (TB) Diagnostics Key Players Headquarters & Area Served
4.4 Global Tuberculosis (TB) Diagnostics Players, Product Type & Application
4.5 Global Tuberculosis (TB) Diagnostics Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Tuberculosis (TB) Diagnostics Market CR5 and HHI
4.6.2 Global Top 5 and 10 Tuberculosis (TB) Diagnostics Players Market Share by Revenue in 2023
4.6.3 2023 Tuberculosis (TB) Diagnostics Tier 1, Tier 2, and Tier
5 TUBERCULOSIS (TB) DIAGNOSTICS MARKET SIZE BY TYPE
5.1 Global Tuberculosis (TB) Diagnostics Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
5.3 Global Tuberculosis (TB) Diagnostics Revenue Market Share by Type (2019-2030)
6 TUBERCULOSIS (TB) DIAGNOSTICS MARKET SIZE BY APPLICATION
6.1 Global Tuberculosis (TB) Diagnostics Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
6.3 Global Tuberculosis (TB) Diagnostics Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Danaher
7.1.1 Danaher Comapny Information
7.1.2 Danaher Business Overview
7.1.3 Danaher Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.1.4 Danaher Tuberculosis (TB) Diagnostics Product Portfolio
7.1.5 Danaher Recent Developments
7.2 Roche
7.2.1 Roche Comapny Information
7.2.2 Roche Business Overview
7.2.3 Roche Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.2.4 Roche Tuberculosis (TB) Diagnostics Product Portfolio
7.2.5 Roche Recent Developments
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Comapny Information
7.3.2 Thermo Fisher Scientific Business Overview
7.3.3 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.3.4 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Product Portfolio
7.3.5 Thermo Fisher Scientific Recent Developments
7.4 BD
7.4.1 BD Comapny Information
7.4.2 BD Business Overview
7.4.3 BD Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.4.4 BD Tuberculosis (TB) Diagnostics Product Portfolio
7.4.5 BD Recent Developments
7.5 Abbott
7.5.1 Abbott Comapny Information
7.5.2 Abbott Business Overview
7.5.3 Abbott Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.5.4 Abbott Tuberculosis (TB) Diagnostics Product Portfolio
7.5.5 Abbott Recent Developments
7.6 Hologic
7.6.1 Hologic Comapny Information
7.6.2 Hologic Business Overview
7.6.3 Hologic Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.6.4 Hologic Tuberculosis (TB) Diagnostics Product Portfolio
7.6.5 Hologic Recent Developments
7.7 Qiagen
7.7.1 Qiagen Comapny Information
7.7.2 Qiagen Business Overview
7.7.3 Qiagen Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.7.4 Qiagen Tuberculosis (TB) Diagnostics Product Portfolio
7.7.5 Qiagen Recent Developments
7.8 BioMerieux
7.8.1 BioMerieux Comapny Information
7.8.2 BioMerieux Business Overview
7.8.3 BioMerieux Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.8.4 BioMerieux Tuberculosis (TB) Diagnostics Product Portfolio
7.8.5 BioMerieux Recent Developments
7.9 Hain Lifescience
7.9.1 Hain Lifescience Comapny Information
7.9.2 Hain Lifescience Business Overview
7.9.3 Hain Lifescience Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.9.4 Hain Lifescience Tuberculosis (TB) Diagnostics Product Portfolio
7.9.5 Hain Lifescience Recent Developments
7.10 Oxford Immunotec
7.10.1 Oxford Immunotec Comapny Information
7.10.2 Oxford Immunotec Business Overview
7.10.3 Oxford Immunotec Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.10.4 Oxford Immunotec Tuberculosis (TB) Diagnostics Product Portfolio
7.10.5 Oxford Immunotec Recent Developments
8 NORTH AMERICA
8.1 North America Tuberculosis (TB) Diagnostics Revenue (2019-2030)
8.2 North America Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
8.2.1 North America Tuberculosis (TB) Diagnostics Revenue by Type (2019-2024)
8.2.2 North America Tuberculosis (TB) Diagnostics Revenue by Type (2025-2030)
8.3 North America Tuberculosis (TB) Diagnostics Revenue Share by Type (2019-2030)
8.4 North America Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
8.4.1 North America Tuberculosis (TB) Diagnostics Revenue by Application (2019-2024)
8.4.2 North America Tuberculosis (TB) Diagnostics Revenue by Application (2025-2030)
8.5 North America Tuberculosis (TB) Diagnostics Revenue Share by Application (2019-2030)
8.6 North America Tuberculosis (TB) Diagnostics Revenue by Country
8.6.1 North America Tuberculosis (TB) Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Tuberculosis (TB) Diagnostics Revenue by Country (2019-2024)
8.6.3 North America Tuberculosis (TB) Diagnostics Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Tuberculosis (TB) Diagnostics Revenue (2019-2030)
9.2 Europe Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
9.2.1 Europe Tuberculosis (TB) Diagnostics Revenue by Type (2019-2024)
9.2.2 Europe Tuberculosis (TB) Diagnostics Revenue by Type (2025-2030)
9.3 Europe Tuberculosis (TB) Diagnostics Revenue Share by Type (2019-2030)
9.4 Europe Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
9.4.1 Europe Tuberculosis (TB) Diagnostics Revenue by Application (2019-2024)
9.4.2 Europe Tuberculosis (TB) Diagnostics Revenue by Application (2025-2030)
9.5 Europe Tuberculosis (TB) Diagnostics Revenue Share by Application (2019-2030)
9.6 Europe Tuberculosis (TB) Diagnostics Revenue by Country
9.6.1 Europe Tuberculosis (TB) Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Tuberculosis (TB) Diagnostics Revenue by Country (2019-2024)
9.6.3 Europe Tuberculosis (TB) Diagnostics Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Tuberculosis (TB) Diagnostics Revenue (2019-2030)
10.2 China Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
10.2.1 China Tuberculosis (TB) Diagnostics Revenue by Type (2019-2024)
10.2.2 China Tuberculosis (TB) Diagnostics Revenue by Type (2025-2030)
10.3 China Tuberculosis (TB) Diagnostics Revenue Share by Type (2019-2030)
10.4 China Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
10.4.1 China Tuberculosis (TB) Diagnostics Revenue by Application (2019-2024)
10.4.2 China Tuberculosis (TB) Diagnostics Revenue by Application (2025-2030)
10.5 China Tuberculosis (TB) Diagnostics Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Tuberculosis (TB) Diagnostics Revenue (2019-2030)
11.2 Asia Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
11.2.1 Asia Tuberculosis (TB) Diagnostics Revenue by Type (2019-2024)
11.2.2 Asia Tuberculosis (TB) Diagnostics Revenue by Type (2025-2030)
11.3 Asia Tuberculosis (TB) Diagnostics Revenue Share by Type (2019-2030)
11.4 Asia Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
11.4.1 Asia Tuberculosis (TB) Diagnostics Revenue by Application (2019-2024)
11.4.2 Asia Tuberculosis (TB) Diagnostics Revenue by Application (2025-2030)
11.5 Asia Tuberculosis (TB) Diagnostics Revenue Share by Application (2019-2030)
11.6 Asia Tuberculosis (TB) Diagnostics Revenue by Country
11.6.1 Asia Tuberculosis (TB) Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Tuberculosis (TB) Diagnostics Revenue by Country (2019-2024)
11.6.3 Asia Tuberculosis (TB) Diagnostics Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Tuberculosis (TB) Diagnostics Revenue (2019-2030)
12.2 MEALA Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
12.2.1 MEALA Tuberculosis (TB) Diagnostics Revenue by Type (2019-2024)
12.2.2 MEALA Tuberculosis (TB) Diagnostics Revenue by Type (2025-2030)
12.3 MEALA Tuberculosis (TB) Diagnostics Revenue Share by Type (2019-2030)
12.4 MEALA Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
12.4.1 MEALA Tuberculosis (TB) Diagnostics Revenue by Application (2019-2024)
12.4.2 MEALA Tuberculosis (TB) Diagnostics Revenue by Application (2025-2030)
12.5 MEALA Tuberculosis (TB) Diagnostics Revenue Share by Application (2019-2030)
12.6 MEALA Tuberculosis (TB) Diagnostics Revenue by Country
12.6.1 MEALA Tuberculosis (TB) Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Tuberculosis (TB) Diagnostics Revenue by Country (2019-2024)
12.6.3 MEALA Tuberculosis (TB) Diagnostics Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Tuberculosis (TB) Diagnostics Market by Type
1.2.1 Global Tuberculosis (TB) Diagnostics Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Culture-Based Diagnostics
1.2.3 Sputum Smear Microscopy
1.2.4 Rapid Molecular Diagnostics
1.2.5 Others
1.3 Tuberculosis (TB) Diagnostics Market by Application
1.3.1 Global Tuberculosis (TB) Diagnostics Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Diagnostic Laboratories
1.3.3 Hospitals
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 TUBERCULOSIS (TB) DIAGNOSTICS MARKET DYNAMICS
2.1 Tuberculosis (TB) Diagnostics Industry Trends
2.2 Tuberculosis (TB) Diagnostics Industry Drivers
2.3 Tuberculosis (TB) Diagnostics Industry Opportunities and Challenges
2.4 Tuberculosis (TB) Diagnostics Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Tuberculosis (TB) Diagnostics Market Perspective (2019-2030)
3.2 Global Tuberculosis (TB) Diagnostics Growth Trends by Region
3.2.1 Global Tuberculosis (TB) Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Tuberculosis (TB) Diagnostics Market Size by Region (2019-2024)
3.2.3 Global Tuberculosis (TB) Diagnostics Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Tuberculosis (TB) Diagnostics Revenue by Players
4.1.1 Global Tuberculosis (TB) Diagnostics Revenue by Players (2019-2024)
4.1.2 Global Tuberculosis (TB) Diagnostics Revenue Market Share by Players (2019-2024)
4.1.3 Global Tuberculosis (TB) Diagnostics Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Tuberculosis (TB) Diagnostics Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Tuberculosis (TB) Diagnostics Key Players Headquarters & Area Served
4.4 Global Tuberculosis (TB) Diagnostics Players, Product Type & Application
4.5 Global Tuberculosis (TB) Diagnostics Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Tuberculosis (TB) Diagnostics Market CR5 and HHI
4.6.2 Global Top 5 and 10 Tuberculosis (TB) Diagnostics Players Market Share by Revenue in 2023
4.6.3 2023 Tuberculosis (TB) Diagnostics Tier 1, Tier 2, and Tier
5 TUBERCULOSIS (TB) DIAGNOSTICS MARKET SIZE BY TYPE
5.1 Global Tuberculosis (TB) Diagnostics Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
5.3 Global Tuberculosis (TB) Diagnostics Revenue Market Share by Type (2019-2030)
6 TUBERCULOSIS (TB) DIAGNOSTICS MARKET SIZE BY APPLICATION
6.1 Global Tuberculosis (TB) Diagnostics Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
6.3 Global Tuberculosis (TB) Diagnostics Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Danaher
7.1.1 Danaher Comapny Information
7.1.2 Danaher Business Overview
7.1.3 Danaher Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.1.4 Danaher Tuberculosis (TB) Diagnostics Product Portfolio
7.1.5 Danaher Recent Developments
7.2 Roche
7.2.1 Roche Comapny Information
7.2.2 Roche Business Overview
7.2.3 Roche Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.2.4 Roche Tuberculosis (TB) Diagnostics Product Portfolio
7.2.5 Roche Recent Developments
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Comapny Information
7.3.2 Thermo Fisher Scientific Business Overview
7.3.3 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.3.4 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Product Portfolio
7.3.5 Thermo Fisher Scientific Recent Developments
7.4 BD
7.4.1 BD Comapny Information
7.4.2 BD Business Overview
7.4.3 BD Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.4.4 BD Tuberculosis (TB) Diagnostics Product Portfolio
7.4.5 BD Recent Developments
7.5 Abbott
7.5.1 Abbott Comapny Information
7.5.2 Abbott Business Overview
7.5.3 Abbott Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.5.4 Abbott Tuberculosis (TB) Diagnostics Product Portfolio
7.5.5 Abbott Recent Developments
7.6 Hologic
7.6.1 Hologic Comapny Information
7.6.2 Hologic Business Overview
7.6.3 Hologic Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.6.4 Hologic Tuberculosis (TB) Diagnostics Product Portfolio
7.6.5 Hologic Recent Developments
7.7 Qiagen
7.7.1 Qiagen Comapny Information
7.7.2 Qiagen Business Overview
7.7.3 Qiagen Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.7.4 Qiagen Tuberculosis (TB) Diagnostics Product Portfolio
7.7.5 Qiagen Recent Developments
7.8 BioMerieux
7.8.1 BioMerieux Comapny Information
7.8.2 BioMerieux Business Overview
7.8.3 BioMerieux Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.8.4 BioMerieux Tuberculosis (TB) Diagnostics Product Portfolio
7.8.5 BioMerieux Recent Developments
7.9 Hain Lifescience
7.9.1 Hain Lifescience Comapny Information
7.9.2 Hain Lifescience Business Overview
7.9.3 Hain Lifescience Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.9.4 Hain Lifescience Tuberculosis (TB) Diagnostics Product Portfolio
7.9.5 Hain Lifescience Recent Developments
7.10 Oxford Immunotec
7.10.1 Oxford Immunotec Comapny Information
7.10.2 Oxford Immunotec Business Overview
7.10.3 Oxford Immunotec Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2019-2024)
7.10.4 Oxford Immunotec Tuberculosis (TB) Diagnostics Product Portfolio
7.10.5 Oxford Immunotec Recent Developments
8 NORTH AMERICA
8.1 North America Tuberculosis (TB) Diagnostics Revenue (2019-2030)
8.2 North America Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
8.2.1 North America Tuberculosis (TB) Diagnostics Revenue by Type (2019-2024)
8.2.2 North America Tuberculosis (TB) Diagnostics Revenue by Type (2025-2030)
8.3 North America Tuberculosis (TB) Diagnostics Revenue Share by Type (2019-2030)
8.4 North America Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
8.4.1 North America Tuberculosis (TB) Diagnostics Revenue by Application (2019-2024)
8.4.2 North America Tuberculosis (TB) Diagnostics Revenue by Application (2025-2030)
8.5 North America Tuberculosis (TB) Diagnostics Revenue Share by Application (2019-2030)
8.6 North America Tuberculosis (TB) Diagnostics Revenue by Country
8.6.1 North America Tuberculosis (TB) Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Tuberculosis (TB) Diagnostics Revenue by Country (2019-2024)
8.6.3 North America Tuberculosis (TB) Diagnostics Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Tuberculosis (TB) Diagnostics Revenue (2019-2030)
9.2 Europe Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
9.2.1 Europe Tuberculosis (TB) Diagnostics Revenue by Type (2019-2024)
9.2.2 Europe Tuberculosis (TB) Diagnostics Revenue by Type (2025-2030)
9.3 Europe Tuberculosis (TB) Diagnostics Revenue Share by Type (2019-2030)
9.4 Europe Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
9.4.1 Europe Tuberculosis (TB) Diagnostics Revenue by Application (2019-2024)
9.4.2 Europe Tuberculosis (TB) Diagnostics Revenue by Application (2025-2030)
9.5 Europe Tuberculosis (TB) Diagnostics Revenue Share by Application (2019-2030)
9.6 Europe Tuberculosis (TB) Diagnostics Revenue by Country
9.6.1 Europe Tuberculosis (TB) Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Tuberculosis (TB) Diagnostics Revenue by Country (2019-2024)
9.6.3 Europe Tuberculosis (TB) Diagnostics Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Tuberculosis (TB) Diagnostics Revenue (2019-2030)
10.2 China Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
10.2.1 China Tuberculosis (TB) Diagnostics Revenue by Type (2019-2024)
10.2.2 China Tuberculosis (TB) Diagnostics Revenue by Type (2025-2030)
10.3 China Tuberculosis (TB) Diagnostics Revenue Share by Type (2019-2030)
10.4 China Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
10.4.1 China Tuberculosis (TB) Diagnostics Revenue by Application (2019-2024)
10.4.2 China Tuberculosis (TB) Diagnostics Revenue by Application (2025-2030)
10.5 China Tuberculosis (TB) Diagnostics Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Tuberculosis (TB) Diagnostics Revenue (2019-2030)
11.2 Asia Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
11.2.1 Asia Tuberculosis (TB) Diagnostics Revenue by Type (2019-2024)
11.2.2 Asia Tuberculosis (TB) Diagnostics Revenue by Type (2025-2030)
11.3 Asia Tuberculosis (TB) Diagnostics Revenue Share by Type (2019-2030)
11.4 Asia Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
11.4.1 Asia Tuberculosis (TB) Diagnostics Revenue by Application (2019-2024)
11.4.2 Asia Tuberculosis (TB) Diagnostics Revenue by Application (2025-2030)
11.5 Asia Tuberculosis (TB) Diagnostics Revenue Share by Application (2019-2030)
11.6 Asia Tuberculosis (TB) Diagnostics Revenue by Country
11.6.1 Asia Tuberculosis (TB) Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Tuberculosis (TB) Diagnostics Revenue by Country (2019-2024)
11.6.3 Asia Tuberculosis (TB) Diagnostics Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Tuberculosis (TB) Diagnostics Revenue (2019-2030)
12.2 MEALA Tuberculosis (TB) Diagnostics Revenue by Type (2019-2030)
12.2.1 MEALA Tuberculosis (TB) Diagnostics Revenue by Type (2019-2024)
12.2.2 MEALA Tuberculosis (TB) Diagnostics Revenue by Type (2025-2030)
12.3 MEALA Tuberculosis (TB) Diagnostics Revenue Share by Type (2019-2030)
12.4 MEALA Tuberculosis (TB) Diagnostics Revenue by Application (2019-2030)
12.4.1 MEALA Tuberculosis (TB) Diagnostics Revenue by Application (2019-2024)
12.4.2 MEALA Tuberculosis (TB) Diagnostics Revenue by Application (2025-2030)
12.5 MEALA Tuberculosis (TB) Diagnostics Revenue Share by Application (2019-2030)
12.6 MEALA Tuberculosis (TB) Diagnostics Revenue by Country
12.6.1 MEALA Tuberculosis (TB) Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Tuberculosis (TB) Diagnostics Revenue by Country (2019-2024)
12.6.3 MEALA Tuberculosis (TB) Diagnostics Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
